[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-tract-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-tract-neoplasms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,81,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100611589","phase-2-study-of-tarlatamab-as-maintenance-treatment-after-chemo-radiotherapy-for-limited-stage-sclc-patients-100611589",false,"NCT07242547","Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients","A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy","MERLIN","Inclusion Criteria:\n\n* Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible.\n* Patients who:\n\n  1. were treated with sequential chemo-radiotherapy\n  2. were treated only with chemotherapy\n* Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1.\n* Has completed chemo-radiation or chemotherapy alone without progression of disease per RECIST v1.1\n* Be male or female ≥18 years of age inclusive, on the day of signing informed consent.\n* Have a life expectancy of at least 3 months from the study start.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to the first dose of study intervention.\n* Toxicities attributed to chemo-radiotherapy treatment have to be resolved to grade ≤1, unless otherwise specified.\n* No clinically significant electrocardiogram (ECG) findings\n* Correct pulmonary function without oxygen supplementation\n* Have voluntarily agreed to participate by giving written consent for the study prior to any specific protocol procedures.\n* Have adequate organ function (hematological and biochemistry parameters).\n\nExclusion Criteria:\n\n* Patients expected to require any other form of radiation therapy for LS-SCLC as concurrent radiotherapy.\n* Extensive-stage SCLC (ES-SCLC) or any previous diagnosis of transformed non-small cell lung cancer. Mixed tumors (SCLC-NSCLC) are not eligible.\n* Has known history of, or active, neurologic paraneoplastic syndrome of autoimmune nature.\n* Has had major surgery within 4 weeks prior to first dose of study interventions.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n* Has known history of a second malignancy other than SCLC, unless potentially curative treatment has been completed with no evidence of malignancy for at least 3 years since the initiation of that therapy.\n* Uncontrolled intercurrent active infection at the time of enrollment requiring systemic therapy.\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* History of solid organ transplantation.\n* Myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association \\>class II) within 6 months prior to first dose of study treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection.\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has a known history of active tuberculosis.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has serious nonhealing wound, ulcer, or bone fracture within 28 days before first dose of study intervention.\n* Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Female subjects who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.\n* Female subjects planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.\n* Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.\n* Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence or use contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.","ALL","18 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll.\n\nPatients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab.\n\nPatients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death.\n\nThe primary objective is to evaluate the Progression free survival (PFS).\n\nPatient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.",[27,28,29,30],"Limited-stage Small-cell Lung Cancer","Carcinoma, Small Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms",[32,33,34,35,36,37],"Non small cell lung cancer","Tarlatamab","Maintenance treatment","Antineoplastic Agents","Chemo-radiotherapy","Immunotherapy","RECRUITING","2026-04-29",{"date":41,"type":42},"2026-05-05","ACTUAL",{"date":44,"type":21},"2026-05-28",{"date":46,"type":21},"2030-06-01",{"name":48,"class":49},"Fundación GECP","OTHER",20,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100586607","phase-2-palace-cemiplimab-trial-according-to-ctdna-levels-100586607","NCT06917573","PALACE: Cemiplimab Trial According to ctDNA Levels","Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients","PALACE","Inclusion Criteria:\n\n* Histologically confirmed stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy\n* PDL1 ≥50%\n* ECOG performance status 0-1\n* Patients aged ≥ 18 years\n* Prior adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment\n* Presence of at least one measurable lesion by CT-scan per RECIST version 1.1\n* Anticipated life expectancy \\>12 weeks\n* Correct hematological, hepatic and renal function\n* Patient consent must be obtained in the appropriate manner as established in the applicable local and regulatory requirements\n* Patients must be accessible for treatment and follow-up\n* Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 3 days before enrolment.\n* All sexually active men and women of childbearing potential must use a highly effective contraceptive method during the study treatment and for a period of at least 4 months following the last administration of trial drugs\n\nExclusion Criteria:\n\n* Patients whose tumors harbor an activating mutation in EGFR, ALK translocation, or ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy\n* Patients with grade ≥2 neuropathy\n* Pregnant or breastfeeding women\n* Patients with a weight loss \\>10% within the previous 3 months\n* Patients with carcinomatous meningitis\n* Patients with a history of other malignant diseases within the past 3 years\n* Patients must have recovered from a major surgery at least 14 days prior to enrolment\n* Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol\n* Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria\n* Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy\n* Patients with a combination of small cell lung cancer and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma\n* Has known allergy or hypersensitivity to components of study drug\n* Significant comorbidities that preclude the administration of chemotherapy according to the investigator's criteria\n* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments\n* Untreated brain metastasis(es) that may be considered active\n* Immunosuppressive corticosteroid doses within 4 weeks prior to the first dose of cemiplimab\n* Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus; or diagnosis of immunodeficiency\n* History of interstitial lung disease or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.\n* History of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments\n* Patients with a history of solid organ transplant\n* Receipt of live vaccines within 30 days of first study treatment\n* Women of childbearing potential, or sexually active men, who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment prior to the start of the first treatment, during the study, and for at least 4 months after the last dose.",{"count":60,"type":21},63,[24],"This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.",[64,65,66,67,29,30],"Non Small Cell Lung Cancer Metastatic","Lung Diseases","Stage IV Non-small Cell Lung Cancer","Stage III Non-small Cell Lung Cancer",[69,70,71,72],"Cemiplimab","ctDNA levels","Chemotherapy","Non-resectable non-small cell lung cancer","2025-11-17",{"date":75,"type":42},"2025-11-19",{"date":77,"type":42},"2025-07-29",{"date":79,"type":21},"2031-12-30",{"name":48,"class":49},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100592093","early-intervention-strategies-for-lung-cancer-100592093","NCT06988943","Early Intervention Strategies for Lung Cancer","Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening","1.Community Health Service Centers (Cluster Level)\n\n1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.\n\n   The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.\n2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results.\n\nCommunity health service centers where researchers cannot collect data or conduct follow-up.\n\n2\\. Screening Subjects (Individual Level)\n\n1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.\n\n   Able to understand and willing to sign the informed consent form, and able to participate in long-term follow-up.\n2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging.\n\nIndividuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.\n\nIndividuals participating in other clinical trials that may affect the results of this study.\n\nIndividuals unable to undergo follow-up.",true,"40 Years","74 Years",{"count":92,"type":21},16000,[94],"NA","Low-dose CT (LDCT）can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.",[29,30,97,98,65,99,100],"Neoplasms by Site","Neoplasms","Respiratory Tract Diseases","Lung Neoplasms",[102,103,104,105],"Screning test","Lung cancer","LDCT","Low-dose CT","2025-05-26",{"date":108,"type":42},"2025-05-30",{"date":110,"type":42},"2024-06-25",{"date":112,"type":21},"2025-06",{"name":114,"class":49},"The First Affiliated Hospital of Guangzhou Medical University",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":132,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":115},"100529757","phase-2-a-phase--clinical-study-of-adebrelimab-combined-with-chemotherapy-and-concurrent-radiotherapy-for-extensive-stage-oligometastatic-sclc-100529757","NCT06177925","A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer","Inclusion Criteria:\n\n* Signed inform consent form\n* Age \\>= 18 years and \\\u003C= 75 years\n* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \\[VALG\\] staging system)，the number of metastatic lesions ≤ 5, the number of metastatic organs ≤ 3, and no previous systemic chemotherapy, radiotherapy or immune checkpoint inhibitor treatment.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Expected survival time ≥ 3 months\n* Patients must submit a pre-treatment tumor tissue sample during the study.\n* Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n* Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 1 week prior to randomization\n* Leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* History of autoimmune disease, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease\n* Prior treatment with immune checkpoint blockade therapies\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid are permitted in the absence of active autoimmune disease.\n* Significant cardiovascular disease\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Treatment with systemic immunosuppressive medications within 1 weeks prior to randomization\n* History of hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, carboplatin or etoposide\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator","75 Years",{"count":125,"type":21},62,[24],"This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin\u002FCisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.",[29,30,97,98,65,99,129,130,100,131],"Carcinoma, Bronchogenic","Bronchial Neoplasms","Small Cell Lung Carcinoma",[133,134,135,71,136],"Extensive stage small cell lung cancer","Oligometastasis","Adebrelimab","Radiotherapy","2023-12-11",{"date":139,"type":42},"2023-12-20",{"date":141,"type":21},"2023-12-10",{"date":143,"type":21},"2026-09-30",{"name":145,"class":49},"Nanfang Hospital, Southern Medical University"]